参考文献: 1. Chey WD, Howden CW, Moss SF, et al. ACG Clinical Guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2024;112(9):1730-1753. 2. TALICIA Prescribing Information. RedHill Biopharma Inc.; 2024. 3. Graham DY, Canaan Y, Maher J, Wiener G, Hulten KG, Kalfus IN. Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: a double-blind, randomized, controlled trial. Ann Intern Med. 2020;172(12):795-802. 4. Kao JY, Almenoff JS, Portenier DD, Sheldon KS. Helicobacter pylori by low-dose rifabutin triple therapy (RHB-105) is unaffected by high body mass index. GastroHep. 2021;3:426-434. 5. Portenier D, Howden CW, Shah SC, et al. Low-dose rifabutin triple therapy for H. pylori is efficacious in patients with obesity and diabetes. Poster presented at Obesity Week Conference. November 2022; San Diego, CA.